<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388984</url>
  </required_header>
  <id_info>
    <org_study_id>TCM9001-04</org_study_id>
    <nct_id>NCT02388984</nct_id>
  </id_info>
  <brief_title>Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy</brief_title>
  <official_title>A Randomized, Double Blind, Multi-Center Study of Compound Danshen Dripping Pills in Patients With Diabetic Retinopathy (Syndrome Of Qi-Stagnation and Blood Stasis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping
      Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compound danshen dripping pills is a kind of traditional Chinese medicine(TCM), consists of
      Danshen (Radix Salviae Miltiorrhizae), Sanqi (Radix Notoginseng) and borneol. This study is
      being conducted to evaluate the efficacy and safety of compound danshen dripping pills in
      patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis), when compared
      with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total effective rate of Fundus changes, the severity of diabetic retinopathy change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms scores of TCM change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected visual acuity change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of macular edema change from baseline at the end of week 24 compared to placebo</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Compound danshen dripping pills</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,20pills,tid. Duration: 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound danshen dripping pills</intervention_name>
    <description>Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.</description>
    <arm_group_label>Compound danshen dripping pills</arm_group_label>
    <other_name>Dantonic®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with non-proliferative diabetic retinopathy(NPDR) and TCM syndrome
             differentiation of qi-stagnation and blood stasis.

          2. aged 30-70 years

          3. voluntary signs the informed consent

        One eye met the inclusion criteria can be used as research object, if both eyes met the
        inclusion criteria, please record respectively, and select one eye for efficacy evaluation
        with reference to the following principles:

        When the two eyes of fundus conditions in different clinical stage, choose the more serious
        one.

        When the two eyes of fundus conditions in the same clinical stage, choose the eye easier
        for clinical operation.

        Exclusion Criteria:

          1. HbAlc＞8%, sustained hyperglycemia.

          2. The patients who have been received the therapy of Retina laser photocoagulation or
             diagnosed with proliferative diabetic retinopathy (one or two eyes).

          3. Diabetic retinopathy caused by type 1 diabetes mellitus.

          4. Combined with glaucoma, uveitis, ocular neuropathy and severe cataract etc.

          5. Combined with primarily severe diseases such as cardiovascular, hepatic，renal illness
             , hemopoietic system disease, and psychosis. Serum transaminase is higher than the
             limit of normal value of 1.5 times.

          6. Diabetic nephropathy with renal failure (Azotemia or Uremia).

          7. For women of child-bearing potential: pregnant or lactating or intending to become
             pregnant. Having any allergic reaction to some drugs.

          8. Participated in other clinical trial within 3 months.

          9. Used drugs for the treatment of diabetic retinopathy within 1 week.

         10. Blood pressure &gt; 160/100 (systolic above 160 or diastolic above 100).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Zhao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tasly Group, Co. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Bei Jing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongfang Hospital, Beijing University of Chinese Medicine</name>
      <address>
        <city>Bei Jing</city>
        <state>Beijing</state>
        <zip>100078</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital, Third Military Medical University</name>
      <address>
        <city>Chong Qing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of TCM</name>
      <address>
        <city>Guang Zhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nan Ning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Institute of Ophthalmology</name>
      <address>
        <city>Zheng Zhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubei Provincial Hospital of TCM</name>
      <address>
        <city>Wu Han</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College,Huazhong University of Science and Technology</name>
      <address>
        <city>Wu Han</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Hunan University of Chinese Medicine</name>
      <address>
        <city>Chang Sha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of TCM</name>
      <address>
        <city>Nan Jing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nan Chang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Changchun University of Chinese Medicine</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang He Eye Hospital</name>
      <address>
        <city>Shen Yang</city>
        <state>Liaoning</state>
        <zip>110141</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yan Tai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shang Hai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital of Chengdu University of TCM</name>
      <address>
        <city>Cheng Du</city>
        <state>Sichuan</state>
        <zip>610075</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

